# TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

> **NCT05247996** · NA · UNKNOWN · sponsor: **The Central Hospital of Lishui City** · enrollment: 98 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **PROCEDURE:** Transcatheter arterial chemoembolization
- **DRUG:** Multi-target Drug Therapy
- **DRUG:** Immunocheckpoint Inhibitor Therapy
- **PROCEDURE:** Systemic Intravenous Chemotherapy

## Key facts

- **NCT ID:** NCT05247996
- **Lead sponsor:** The Central Hospital of Lishui City
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247996, "TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05247996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*